Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah C Rutherford

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Blood Advances|April 17, 2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYASarah C Rutherford, Michael Herold, Wolfgang Hiddemann, et al.
Blood Advances|January 24, 2024
Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphomaSarah C Rutherford, Jun Yin, Levi D Pederson, et al.
Blood|July 4, 2018
Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterationsSarah C Rutherford, Angela A Fachel, Sheng Li, et al.
Blood Advances|September 28, 2021
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphomaMichael Dickinson, Javier Briones, Alex F Herrera, et al.
Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.
Blood|February 16, 2023
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCLJia Ruan, Alison Moskowitz, Neha Mehta-Shah, et al.
Blood Advances|November 25, 2025
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell LymphomaJia Ruan, David A Bond, Bijal D Shah, et al.
Cancer Research|October 6, 2023
XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer CellsRossella Marullo, Sarah C Rutherford, Maria V Revuelta, et al.
Leukemia & Lymphoma|February 15, 2021
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphomaNina Orfali, Yuliya Jhanwar, Calvin Koo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2022
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical TrialsSarah C Rutherford, Jun Yin, Levi Pederson, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Blood Advances|April 17, 2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYASarah C Rutherford, Michael Herold, Wolfgang Hiddemann, et al.
Blood Advances|January 24, 2024
Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphomaSarah C Rutherford, Jun Yin, Levi D Pederson, et al.
Blood|July 4, 2018
Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterationsSarah C Rutherford, Angela A Fachel, Sheng Li, et al.
Blood Advances|September 28, 2021
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphomaMichael Dickinson, Javier Briones, Alex F Herrera, et al.
Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.
Blood|February 16, 2023
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCLJia Ruan, Alison Moskowitz, Neha Mehta-Shah, et al.
Blood Advances|November 25, 2025
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell LymphomaJia Ruan, David A Bond, Bijal D Shah, et al.
Cancer Research|October 6, 2023
XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer CellsRossella Marullo, Sarah C Rutherford, Maria V Revuelta, et al.
Leukemia & Lymphoma|February 15, 2021
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphomaNina Orfali, Yuliya Jhanwar, Calvin Koo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2022
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical TrialsSarah C Rutherford, Jun Yin, Levi Pederson, et al.
Pageof 4